• Home
  • NEW DAY MEDICINE
  • 10 (84) 2025
  • 20 -10 (84) 2025 - Mirzuraev E.M., Adambaev Z.I. - COMPARATIVE ANALYSIS OF CLINICAL-NEUROLOGICAL AND BIOCHEMICAL PARAMETERS IN VARIOUS FORMS OF SPINAL PATHOLOGY: FROM PROTRUSIONS TO COMBINED LESIONS

20 -10 (84) 2025 - Mirzuraev E.M., Adambaev Z.I. - COMPARATIVE ANALYSIS OF CLINICAL-NEUROLOGICAL AND BIOCHEMICAL PARAMETERS IN VARIOUS FORMS OF SPINAL PATHOLOGY: FROM PROTRUSIONS TO COMBINED LESIONS

COMPARATIVE ANALYSIS OF CLINICAL-NEUROLOGICAL AND BIOCHEMICAL PARAMETERS IN VARIOUS FORMS OF SPINAL PATHOLOGY: FROM PROTRUSIONS TO COMBINED LESIONS

Mirzuraev E.M. - Center for the Development of Professional Qualifications of Medical Workers under the Ministry of Health of the Republic of Uzbekistan

Adambaev Z.I. - Urgench branch of the Tashkent Medical Academy

Soliyeva N.O. - Andijan State Medical Institute

Resume

Objective: To compare clinical manifestations and biochemical markers in different forms of degenerative-dystrophic spinal diseases (DDSD) to optimize therapeutic strategies. Materials and Methods: A cross-sectional study included 120 patients with: protrusions (n=38), isolated hypertrophy of the ligamentum flavum (n=6), herniations (n=23), combined herniations and protrusions (n=27), and combined pathology (herniations + ligamentum flavum hypertrophy, n=26). Clinical scales (VAS, Scandinavian Pain Questionnaire, BDI, Oswestry, vertebrological symptoms, DN4) and biomarkers (MMP-8, MMP-9, TIMP-1, CRP, IL-6) were evaluated. Results: A severity gradient was identified: protrusions (VAS: 3.5±0.1; MMP-9: 18.5±0.4 ng/ml) → ligamentum flavum hypertrophy (VAS: 5.0±0.4; IL-6: 12.6±1.1 pg/ml) → herniations → herniations+protrusions → combined pathology (VAS: 8.7±0.1; MMP-9: 80.3±2.2 ng/ml). Combination of herniations and ligamentum flavum hypertrophy caused synergism with 1.3–1.5-fold biomarker elevation. Correlations were established between MMP-9 and pain (r>0.8) and IL-6 and neuropathy (r>0.7). Conclusions: Hypertrophy of the ligamentum flavum is an independent pathological factor. Its combination with herniations creates synergism with maximal activation of destructive-inflammatory processes. MMP-9 and IL-6 are key predictors of severity, justifying a differentiated approach to treatment and monitoring of DDSD.

Keywords: degenerative-dystrophic spinal diseases, protrusions, disc herniation, ligamentum flavum hypertrophy, matrix metalloproteinases, interleukin-6, biomarkers, pain, disability.

First page

107

Last page

112

For citation:Mirzuraev E.M., Adambaev Z.I., Soliyeva N.O. - COMPARATIVE ANALYSIS OF CLINICAL-NEUROLOGICAL AND BIOCHEMICAL PARAMETERS IN VARIOUS FORMS OF SPINAL PATHOLOGY: FROM PROTRUSIONS TO COMBINED LESIONS//New Day in Medicine 10(84)2025 107-112 https://newdayworldmedicine.com/en/new_day_medicine/10-84-2025

List of References

  1. Global Burden of Disease Study 2019 Collaborators. Global, regional, and national burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1206-1222.
  2. Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik JG. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA. 2010;303(13):1259-1265.
  3. Vergroesen PP, Kingma I, Emanuel KS, Hoogendoorn RJ, Welting TJ, van Royen BJ, van Dieën JH, Smit TH. Mechanics and biology in intervertebral disc degeneration: a vicious circle. Eur Spine J. 2015;24 Suppl 4:435-442.
  4. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. Eur Spine J. 2015;24(9):1925-1934.
  5. Wang Y, Chen J, Li K, Zhang Y, Wang X, Li C, Wang H, Liu Z. IL-6 induces the apoptosis of nucleus pulposus cells via the JAK/STAT signaling pathway in intervertebral disc degeneration. Int Immunopharmacol. 2021;99:108-164.
  6. Kepler CK, Ponnappan RK, Tannoury CA, Risbud MV, Anderson DG. The molecular basis of intervertebral disc degeneration and herniation: a review. Spine J. 2013;15(9):2013-2021.
  7. Chen J, Yan W, Setton LA, Liu Z, Wang H, Chen Q, Li X, Kang JD. Interaction between inflammation and matrix degradation in intervertebral disc degeneration. J Orthop Res. 2020;38(1):5-14.
  8. Ohtori S, Inoue G, Miyagi M, Takahashi K. Pathomechanisms of discogenic low back pain in humans. Spine J. 2015;15(9):2013-2021.
  9. Takatalo J, Karppinen J, Niinimäki J, Taimela S, Näyhä S, Järvelin MR, Kyllönen E, Tervonen O. Prevalence of degenerative imaging findings in the lumbar spine in relation to modic changes. Osteoarthritis Cartilage. 2017;25(1):129-135.
  10. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):480-492.
  11. Chen J, Li K, Zheng Y, Wang Y, Wang X, Liu Z, Wang H. Targeting IL-6 in intervertebral disc degeneration: a promising therapeutic strategy. J Cell Mol Med. 2022;26(2):345-357.
  12. Wang Y, Wang X, Li C, Liu Z, Chen J. Standardization of biomarker measurement in degenerative disc disease: a systematic review. Clin Biochem. 2021;88:105-112.

    file

    download